

# SECURITIES AND EXCHANGE COMMISSION

## FORM 25

Notification filed by issuer to voluntarily withdraw a class of securities from listing and registration on a national securities exchange

Filing Date: **2013-01-28**  
SEC Accession No. [0001354488-13-000321](#)

([HTML Version](#) on [secdatabase.com](#))

### FILER

---

**PERNIX THERAPEUTICS HOLDINGS, INC.**

CIK: [1024126](#) | IRS No.: [330724736](#) | State of Incorporation: **MD** | Fiscal Year End: **1231**  
Type: **25** | Act: **34** | File No.: [001-14494](#) | Film No.: [13549664](#)  
SIC: **2834** Pharmaceutical preparations

Mailing Address  
*33219 FOREST WEST  
STREET  
MAGNOLIA TX 77354*

Business Address  
*33219 FOREST WEST  
STREET  
MAGNOLIA TX 77354  
(832) 934-1825*

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR  
REGISTRATION UNDER SECTION 12(b) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-14494

**PERNIX THERAPEUTICS HOLDINGS, INC. and NYSE MKT, LLC**

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

**10003 Woodloch Forest Drive  
The Woodlands, TX 77380  
(832) 934-1825**

---

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

---

---

**Common Stock, par value \$0.01 per share**

---

(Description of class of securities))

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

- 17 CFR 240.12d2-2(a)(1)  
 17 CFR 240.12d2-2(a)(2)  
 17 CFR 240.12d2-2(a)(3)  
 17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Pernix Therapeutics Holdings, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

Date: January 25, 2013

By: /s/ Cooper C. Collins  
Cooper C. Collins, President,  
Chief Executive Officer, and  
Director